Technology from School of Pharmacy enables clinical trial on new treatment for ulcerative colitis

Monoclonal antibodies constitute a large part of the pharmaceutical market and is a superior modality in treating many diseases. As therapeutics, they are administered via injection, a less-than-ideal therapy for many patients suffering from life-long conditions. US company Mage Biologics, established in 2023, raised $28 million to take their novel oral antibody therapy for ulcerative colitis into clinical studies. This best-in-class monoclonal antibody, engineered for enhanced potency and tissue penetration upon oral delivery, is being delivered to the intestinal tract through technologies developed in the Basit Research Group at the UCL School of Pharmacy. The Phase I clinical trial (NCT06363383) on the innovative treatment is currently on-going, and with expected completion by mid 2025, the outcomes from the study are greatly anticipated to be announced later in the year.

• https://www.biospace.com/tillotts-pharma-and-tvm-capital-life-science-announce-formation-of-mage-biologics-to-develop-innovative-oral-antibody-therapy-for-ulcerative-colitis
• https://www.samedanltd.com/press-releases/mage-biologics-announces-first-subject-dosed-in-a-phase-1-trial-with-mb-001-an-orally-administered-antibody-for-inflammatory-bowel-disease-2/
• Basit Research Group
• Basit Linked in

• Prof Abdul Basit (a.basit@ucl.ac.uk)